Liquid biopsy and minimal residual disease - latest advances and implications for cure

Klaus Pantel; Catherine Alix-Panabières

doi:10.1038/s41571-019-0187-3

Liquid biopsy and minimal residual disease - latest advances and implications for cure

Standard

Liquid biopsy and minimal residual disease - latest advances and implications for cure. / Pantel, Klaus; Alix-Panabières, Catherine.

In: NAT REV CLIN ONCOL, Vol. 16, No. 7, 07.2019, p. 409-424.

Research output: SCORING: Contribution to journal › SCORING: Review article › Research

Harvard

Pantel, K & Alix-Panabières, C 2019, 'Liquid biopsy and minimal residual disease - latest advances and implications for cure', NAT REV CLIN ONCOL, vol. 16, no. 7, pp. 409-424. https://doi.org/10.1038/s41571-019-0187-3

APA

Pantel, K., & Alix-Panabières, C. (2019). Liquid biopsy and minimal residual disease - latest advances and implications for cure. NAT REV CLIN ONCOL, 16(7), 409-424. https://doi.org/10.1038/s41571-019-0187-3

Vancouver

Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. NAT REV CLIN ONCOL. 2019 Jul;16(7):409-424. https://doi.org/10.1038/s41571-019-0187-3

Bibtex

@article{d0e6e99c892d43d8a07da9872664bfae,

title = "Liquid biopsy and minimal residual disease - latest advances and implications for cure",

abstract = "Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free tumour DNA (ctDNA). Highly sensitive liquid biopsy assays have been developed that can now be applied to detect and characterize minimal residual disease (MRD), which reflects the presence of tumour cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological signs of metastasis or residual tumour cells left behind after local therapy that eventually lead to local recurrence. This application is the new frontier of liquid biopsy analyses, which are challenged by the very low concentrations of CTCs and ctDNA in blood samples. In this Review, we discuss the key technologies that can be used to detect and characterize CTCs in surveillance of MRD and provide a brief overview of similar roles of ctDNA analyses. We then focus on the current clinical data on the use of CTCs and ctDNA in the detection and monitoring of MRD and in obtaining information on therapeutic targets and resistance mechanisms relevant to the management of individual patients with cancer.",

keywords = "Journal Article, Review",

author = "Klaus Pantel and Catherine Alix-Panabi{\`e}res",

year = "2019",

month = jul,

doi = "10.1038/s41571-019-0187-3",

language = "English",

volume = "16",

pages = "409--424",

journal = "NAT REV CLIN ONCOL",

issn = "1759-4774",

publisher = "NATURE PUBLISHING GROUP",

number = "7",

}

RIS

TY - JOUR

T1 - Liquid biopsy and minimal residual disease - latest advances and implications for cure

AU - Pantel, Klaus

AU - Alix-Panabières, Catherine

PY - 2019/7

Y1 - 2019/7

N2 - Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free tumour DNA (ctDNA). Highly sensitive liquid biopsy assays have been developed that can now be applied to detect and characterize minimal residual disease (MRD), which reflects the presence of tumour cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological signs of metastasis or residual tumour cells left behind after local therapy that eventually lead to local recurrence. This application is the new frontier of liquid biopsy analyses, which are challenged by the very low concentrations of CTCs and ctDNA in blood samples. In this Review, we discuss the key technologies that can be used to detect and characterize CTCs in surveillance of MRD and provide a brief overview of similar roles of ctDNA analyses. We then focus on the current clinical data on the use of CTCs and ctDNA in the detection and monitoring of MRD and in obtaining information on therapeutic targets and resistance mechanisms relevant to the management of individual patients with cancer.

AB - Liquid biopsy has been introduced as a new diagnostic concept predicated on the analysis of circulating tumour cells (CTCs) or circulating tumour-derived factors, in particular, cell-free tumour DNA (ctDNA). Highly sensitive liquid biopsy assays have been developed that can now be applied to detect and characterize minimal residual disease (MRD), which reflects the presence of tumour cells disseminated from the primary lesion to distant organs in patients who lack any clinical or radiological signs of metastasis or residual tumour cells left behind after local therapy that eventually lead to local recurrence. This application is the new frontier of liquid biopsy analyses, which are challenged by the very low concentrations of CTCs and ctDNA in blood samples. In this Review, we discuss the key technologies that can be used to detect and characterize CTCs in surveillance of MRD and provide a brief overview of similar roles of ctDNA analyses. We then focus on the current clinical data on the use of CTCs and ctDNA in the detection and monitoring of MRD and in obtaining information on therapeutic targets and resistance mechanisms relevant to the management of individual patients with cancer.

KW - Journal Article

KW - Review

U2 - 10.1038/s41571-019-0187-3

DO - 10.1038/s41571-019-0187-3

M3 - SCORING: Review article

C2 - 30796368

VL - 16

SP - 409

EP - 424

JO - NAT REV CLIN ONCOL

JF - NAT REV CLIN ONCOL

SN - 1759-4774

IS - 7

ER -